Halozyme Therapeutics Aktie

56,98 EUR ±0,00 EUR ±0,00 %

10:33:54

FSE

62,49 USD +1,45 USD +2,38 %

vorbörslich13:12:24

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.7,05 Mrd. EUR

KGV13,93Div. Rendite0,00%

WKNA0DLHS

ISINUS40637H1095

SymbolHALO

Halozyme Therapeutics Aktien News

Sortieren:Datum Meistgelesen

09.05.24finanzen.netHalozyme Therapeutics verkündete Quartalsergebnis zum jüngsten Jahresviertel

08.05.24PR NewswireHalozyme to Participate in Upcoming Investor Conferences

08.05.24ZacksHalozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

07.05.24ZacksHalozyme Therapeutics (HALO) Q1 Earnings Beat Estimates

07.05.24PR NewswireHALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS

07.05.24BenzingaExpert Ratings For Halozyme Therapeutics

06.05.24ZacksHalozyme Therapeutics (HALO) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates

06.05.24finanzen.netAusblick: Halozyme Therapeutics legt die Bilanz zum abgelaufenen Quartal vor

30.04.24ZacksHalozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

25.04.24PR NewswireMahesh Krishnan Elected to Halozyme's Board of Directors

24.04.24ZacksWhy Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term

23.04.24PR NewswireHalozyme to Report First Quarter 2024 Financial and Operating Results

18.04.24ZacksHalozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

18.04.24ZacksHalozyme Therapeutics (HALO) Upgraded to Buy: Here's What You Should Know

16.04.24Benzinga9 Analysts Have This To Say About Halozyme Therapeutics

04.04.24ZacksHalozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy?

21.03.24ZacksWhy Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?

19.03.24ZacksHere's Why Halozyme Therapeutics (HALO) is a Strong Value Stock

27.02.24PR NewswireHalozyme to Participate in Upcoming Investor Conferences

22.02.24finanzen.netHalozyme Therapeutics stellte Zahlen zum jüngsten Quartal vor

20.02.24PR NewswireHALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS

19.02.24finanzen.netAusblick: Halozyme Therapeutics präsentiert Quartalsergebnisse

08.02.24PR NewswireHalozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results

29.01.24PR NewswireHalozyme Announces Takeda Received European Commission Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

18.01.24PR NewswireHalozyme Announces argenx Received Approval in Japan for VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Co-Formulated with ENHANZE® for Generalized Myasthenia Gravis

16.01.24PR NewswireHalozyme Announces Takeda Receives FDA Approval for HYQVIA® Co-formulated with ENHANZE® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

16.01.24PR NewswireHalozyme Announces Roche Receives European Commission Approval of Tecentriq® SC with ENHANZE® Representing the EU's First Subcutaneous PD-(L)1 Cancer Immunotherapy for Multiple Cancer Types

12.01.24PR NewswireHalozyme to Host Investor Business Forum and Long-Term Outlook Call

27.11.23PR NewswireHalozyme to Present at Upcoming Investor Conferences

16.11.23PR NewswireHalozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis

07.11.23finanzen.netHalozyme Therapeutics: Das sind die jüngsten Quartalszahlen

06.11.23PR NewswireHALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS

06.11.23PR NewswireHalozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease

05.11.23finanzen.netAusblick: Halozyme Therapeutics stellt das Zahlenwerk zum vergangenen Quartal vor

30.10.23PR NewswireHalozyme To Report Third Quarter 2023 Financial and Operating Results

19.10.23PR NewswirePositive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Cle...

16.10.23PR NewswireUpdate: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opport...

16.10.23PR NewswireHalozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

31.08.23PR NewswireHalozyme to Present at Upcoming Investor Conferences

29.08.23PR NewswireHalozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Halozyme Therapeutics News

Halozyme Therapeutics News: auf dieser Seite finden Sie alle Halozyme Therapeutics News und Nachrichten zur Halozyme Therapeutics Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Halozyme Therapeutics News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Halozyme Therapeutics News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.